Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake

Amgen, Sandoz begin biosimilar trial with top-selling Enbrel at stake

Source: 
Biopharma Dive
snippet: 

A high-stakes case pitting Amgen against Novartis' Sandoz kicked off in court this week, with potential to change the course of Amgen's multi-billion dollar Enbrel business and shake up the biosimilars market in the U.S.